Phospholipase D, peanut
Based on 1 Customer Validation
Phospholipase D, peanut is a phospholipase D (EC 3.1.4.4) of the PLD superfamily found in peanuts, acting as a phosphodiesterase and signaling enzyme with activity toward phosphatidylcholine. Phospholipase D hydrolyzes phosphatidylcholine to phosphatidic acid and choline, and catalyzes transphosphatidylation reactions. Phospholipase D can be used for the research of myocardial disease, ischemic heart disease, congestive heart failure, diabetic cardiomyopathy, cardiac hypertrophy, vascular abnormalities, breast cancer, gastric cancer, renal cancer, colorectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 9001-87-0
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Phospholipase Isoforms
More
Biological Activity
Description
In Vitro
Phospholipase D hydrolyzes choline phospholipids to quantify propargylcholine incorporation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
EC Number
3.1.4.4
Enzyme Activity
≥60 U/mg soild
Unit Definition
One unit is defined as the amount of enzyme that catalyze the release of 1 μmol of choline from L-αphosphatidylcholineyolk) per hour at pH 5.6 and 30°C
Chemical Information
-
CAS No. 9001-87-0
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Phospholipase D, peanut]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cardiac Morphometry
Cardiac morphometry is based on quantitative histological and stereological assessment of myocardial structure, including cardiomyocyte size, number, and extracellular matrix composition, to evaluate cardiac growth and remodeling under physiological or pathological conditions. Design-based stereology is considered a reference framework for obtaining unbiased estimates of structural parameters such as cardiomyocyte number, volume, and tissue architecture, enabling quantitative comparison across experimental groups. Histological image-based morphometry further enables measurement of cardiomyocyte cross-sectional area and collagen deposition using microscopy combined with image analysis software, allowing assessment of hypertrophy and fibrosis in cardiac remodeling models. These morphometric readouts reflect underlying biological processes such as cardiomyocyte hypertrophy, loss, or structural reorganization during disease progression or experimental stress.
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shukla SD, Halenda SP. Phospholipase D in cell signalling and its relationship to phospholipase C. Life sciences. 1991;48(9):851-66. [Content Brief]
[2]. Selvy PE, et al. Phospholipase D: enzymology, functionality, and chemical modulation. Chem Rev. 2011 Oct 12;111(10):6064-119. [Content Brief]
[3]. Jao CY, Roth M, Welti R, et al.. Metabolic labeling and direct imaging of choline phospholipids in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2009 Sep 08;106(36):15332-7. [Content Brief]
[4]. Tappia PS, et al. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med. 2006 Aug 1;41(3):349-61. [Content Brief]
[5]. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res. 2003 Sep;1(11):789-800. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)